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COMMON MEFV MUTATIONS AND HLA-B*51 FREQUENCIES IN 
ARMENIAN AND TURKISH POPULATIONS LıVıNG ıN ıSTANBUL 
 
SUMMARY 
Familial Mediterranean Fever (FMF) and Behçet Disease (BD) are two 
autoinflammatory diseases prevalent in people from Middle-East and Mediterranean 
ancestory. The frequency of FMF is found to be between 1 to 2.5 in 1000, and the 
frequency of BD 4 in 1000 from previous studies conducted in Turkey. A recent 
study performed on Armenian Turkish citizens states that the frequency of FMF is 
higher than the Turkish population (%0.7) and that the frequency of BD was lower  
within the same group (<1/500). These findings led us to propose that the genetic 
factors have an important role in the aetiology of these two diseases. 
The gene for FMF is Mediterrenean Fever Gene (MEFV) and there are more than 70 
mutations which have been characterized. Among these, four mutations (M694V, 
M694I, M680I, V726A) and one polymorphism (E148Q) are more commonly seen 
in the FMF patients. These mutations are reported to be approximately 85% in 
patients and 10-20 % in the healthy population. 
The association between HLA-B*51 and BD have been implied in many studies. The 
carrier rate of HLA-B*51 was reported to be between 50-80 % in patients and 20-30 
% in healthy population. The occurrence of HLA-B*51 allele and the frequency of 
BD correlate with each other. For instance, in populations where the carrier rate of 
HLA-B*51 is lower, the frequency of BD is also lower. 
We wanted to reveal the frequency of the MEFV mutations and HLA-B*51 
frequencies in Armenian Turkish citizens and Turkish population living in the same 
environment, and clarify if there is any difference in mutation frequencies between 
these two populations with respect to disease frequencies. 
For this purpose, saliva samples were collected from 115 Armenians working in the 
administration department of Armenian schools in Istanbul and from 98 Turkish 
students studying in Cerrahpaşa Medical Faculty. Mutation/polymorphism analysis 
revealed that there isn’t any difference in the frequencies of MEFV mutations and of 
HLA-B*51 phenotypes between the Armenian and the Turkish groups. These results 
may point to other location/loci for FMF and BD. 
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İSTANBULDA YAŞAYAN ERMENİ VE TÜRK TOPLUMLARINDAKİ 
YAYGıN MEFV MUTASYONLARı VE HLA-B*51 GEN FREKANSLARI  
 
 
ÖZET 
Ailevi Akdeniz Ateşi ve Behçet Hastalığı, Ortadoğu ve Akdeniz toplumlarında, 
dünyanın diğer bölgelerine kıyasla daha sık görülen otoenflamatuvar hastalıklardır. 
Türkiye’de yapılan çalışmalarda Ailevi Akdeniz Ateşi sıklığının 1000’de 1 ila 2.5  
arasında değiştiği, Behçet hastalığının sıklığının ise 1000’de 4 olduğu  gözlenmiştir. 
Yakın zamanda İstanbul’da Ermeni kökenli Türkiye Cumhuriyeti vatandaşlarında 
yapılan bir çalışmada, bu toplumda Ailevi Akdeniz Ateşinin Türklere oranla daha sık 
(% 0.7), Behçet Hastalığının ise daha nadir olduğu (<1/ 500) bulunmuştur. Bu 
bulgular, her iki hastalığın etiyolojisinde de genetik faktörlerin önemli rolü olduğunu 
düşündürmektedir.   
Ailevi Akdeniz Ateşi hastalığına Mediterranean Fever (MEFV) genindeki 
mutasyonların yol açtığı bilinmektedir. Şu ana kadar tanımlanan mutasyonların sayısı 
70’den fazladır; ancak bunlardan yalnızca 4 mutasyon (M694V, M694I, M680I, 
V726A) ve bir polimorfizm (E148Q)  daha sık görülmektedir. Yapılan çalışmalarda, 
bu mutasyonların hasta kişilerde % 85, sağlıklı kişilerde ise % 10-20 oranında olduğu 
bildirilmektedir.   
Öte yandan Behçet hastalığı ile HLA-B*51 geni arasında olası bir ilişki varolduğu da 
çeşitli çalışmalarda belirtilmiştir. HLA-B*51 taşıyıcılığı, Behçet hastalığı olan 
bireylerde % 50-80, sağlıklı kişilerde ise % 20-30 oranında bildirilmektedir. Behçet 
hastalığının sıklığı toplumdaki HLA-B*51 taşıyıcılığına paralel seyretmektedir. 
Örneğin, HLA-B*51 sıklığının az olduğu toplumlarda Behçet hastalığı da nadirdir.    
Bu çalışmada, T.C. Ermeni ve Türk vatandaşlarında MEFV gen mutasyonu ve HLA-
B*51 gen taşıyıcılığını araştırmak ve bu iki toplumun mutasyon sıklıkları arasındaki 
farkları hastalık sıklıklarını göz önünde bulundurarak ortaya çıkartmak 
amaçlanmaktadır. 
Bu doğrultuda İstanbul’daki Ermeni okullarının idari bölümünde çalışan 115 Ermeni 
ve Cerrahpaşa Tıp Fakültesi’nde okuyan 98 Türk vatandaştan tükürük örneği 
toplandı. Mutasyon/polimorfizm analizleri sonucu bu iki toplumun MEFV mutasyon 
ve HLA-B*51 frekansları arasında belirgin bir fark gözlenmedi. Bu sonuçlar FMF ve 
Behçet hastalığında diğer lokasyon veya lokasyonların rol oynayabileceğine işaret 
etmektedir. 
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1. INTRODUCTION 
Autoinflammatory diseases were first defined for the hereditary periodic diseases by 
Kastner et al. in 1999. They are mainly caused by mutations on the innate immune 
system genes, as well as mutations in genes encoding proteins involved in apoptotic 
and cytokine processing pathways [1,2]. A relative lack of autoimmune pathology, 
like pathogenic high-titer autoantibodies or antigen-specific T cells is the 
characteristics of these diseases. Also environmental factors and background genetic 
effects may play a role in the formation of different clinical manifestations [2]. 
Although the immune system is regulated by many mechanisms, its occasional 
failures may lead to autoimmune or autoinflammatory diseases. Autoimmune 
diseases result from the dysfunctional activation of B and T cells, which lead to the 
production of receptors and specific antibodies to self-antigens. On the other hand, 
neither autoantigens nor autoantibodies are playing a role for the autoinflammation. 
Inflammation episodes may occur without any detectable causes [1]. 
Familial Mediterranean Fever (FMF) and Behçet Disease (BD) are both 
inflammatory diseases that are mainly seen in Middle Eastern and Mediterranean 
populations [3]. FMF is a hereditary periodic fever, which is found to be linked to 
MEFV gene [3,4], and BD is a polyfactorial vasculitis, linked to major 
histocompatibility complex (MHC) [3,5]. FMF was first observed in 1908 but was 
defined later in 1945 by Siegal  [6,7]. The first case of FMF in Turkey was reported 
one year later, in 1946 [6]. On the other hand, BD is named after Dr. Hulusi Behçet, 
the dermatologist who demonstrated it for the first time [8]. 
1.1 Characteristics of FMF and BD 
FMF is characterized by acute attacks of fever; abdominal, thoracic and joint pain 
due to peritonitis, pleuritis and synovitis; and also by erysipelas-like erythema [4,9]. 
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The recurrent attacks of fever may cause amyloid AA protein accumulation, and the 
accumulation of this protein in the kidneys may lead to death [4]. The precursor of 
the amyloid fibrils, serum amyloid A (SAA) is an acute phase reactant, which has a 
role in mediating inflammation and is found to be elevated in FMF patients during 
and between the attacks [10]. Two phenotypes of FMF are defined according to the 
presence of amyloidosis as fist manifestation: in phenotype I, the attacks of fever 
appear first and in phenotype II, amyloidosis is initially observed [9]. Also, another 
phenotype was categorized as phenotype III for individuals who have the mutant 
genotype but does not show the FMF phenotype [8]. The existence of the phenotype 
III, with the results of other studies showing the dominant inheritance of FMF in 
some families [11], has compromised the autosomal recessive inheritance of FMF as 
previously described [7]. Furthermore the variation of the occurrence of amyloidosis 
in different ethnic groups may point to separate genetic loci other than the FMF gene 
[10].  
AA type amyloidosis is also a rare but an important complication of BD although it 
is not very commonly encountered as in FMF patients [12, 13]. Diagnosis of BD is 
effectuated via clinical testing due to the absence of laboratory findings 
characterizing the disease. According to the international study group classification 
criteria, recurrent oral ulcerations with two of the following is sufficient for the 
designation of BD: recurrent genital ulcerations, ocular lesions, typical skin lesions 
and a positive pathergy (skin hyper reactivity) test [14].  
Colchicine is generally used to treat patients who suffer from FMF and/or BD. Its 
action mechanism involves preventing fever attacks and amyloidosis [10,13,14]. 
However, some patients don’t respond to colchicine therapy. Interferon-γ and anti-
TNF-α agents have been reported to be efficient for colchicine-resistant patients 
[14,15]. 
The age of onset of FMF is variable. Generally the first attacks are observed before 
the age of 20; moreover onset before 10 years is also a common case [7]. Occurrence 
of the attacks after 40 years is also reported; still they had a milder form of disease 
with abdominal attacks as the only symptom of FMF in many cases and without 
other types of chronic manifestations like amyloidosis or chronic arthritis [16]. 
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A milder form of BD is also observed for late onset (after 40 years). Furthermore, 
both diseases show a severe course in young males [17,18]. The general age of onset 
for BD is the third decade of life [17].  
1.2 Relationship between FMF and BD 
The coexistence of FMF and BD has been observed in many countries. Birlik et al. 
reported a Turkish patient having both FMF and BD in 1998. In 2000, Schwartz et 
al. have reported 39 patients having BD among 4000 non-Ashkenazi Jewish FMF 
patients. 14 Turkish patients among 2716 (0.5 %) were reported to possess the two 
diseases at the same time by the Turkish FMF Study Group in 2005. The same year, 
Matsuda et al. reported a 15 year-old Japanese patient with the same case. 
The concomitant occurrence of the two diseases may be due to the neutrophil and 
monocyte involvement in both of the diseases [13,19].  The serosal fluids of FMF 
patients have higher amounts of neutrophils during the attacks. Also, lesions of BD 
patients show neutrophil enhancement without any sign of bacterial presence [13]. 
Neutrophils participate to the regulation of the inflammatory response subsequent to 
an inflammatory stimulus, by producing soluble proinflammatory and 
antiinflammatory mediators. Monocytes play a central role in the coordination of 
inflammatory processes [20]. Pyrin, the product of MEFV gene, which is highly 
expressed in neutrophils, monocytes and dendritic cells is shown to be involved in 
both diseases [15,21]. 
1.3 MEFV gene, pyrin protein and its role in the formation of the inflammasome 
MEFV gene has been found to be located on the short arm of chromosome 16 via 
linkage analysis [10]. In 1997, two consortia have cloned this gene (International 
FMF Consortium and French FMF Consortium). MEFV contains 10 exons and its 
RNA transcript encodes a protein composed of 781 amino acids [22]. This protein is 
called pyrin (fire in Greek) by the International FMF consortium, and marenostrin 
(coming from marenostrum in Latin, meaning Mediterranean Sea) by the French 
FMF consortium [15,23]. 
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Figure 1.1. Pyrin protein and its different domains [22] 
The pyrin domain on the exon 1 encodes a death domain. The exons between 2 and 
10 contain other known motifs like bZIP on the second exon, a transcription factor 
basic domain; B box zinc finger on the exon 3; Coiled coil domain spanned on exons 
3 to 8; and on the exon 10, where the majority of the mutations are found, the 
B30.2/SPRY/rfp domain composing the C-terminal domain [22]. 
Pyrin is mainly found in granulocytes, monocytes, dendritic cells; synovial, 
peritoneal, and skin-derived fibroblasts and has an important role in innate immunity 
[24]. It is up regulated by pro-inflammatory cytokines like LPS 
(Lipopolysaccharides), TNF-α, and IFN-γ, and down-regulated by anti-inflammatory 
cytokines like IL-4, IL-10, and TGF-ß [22]. This fact may lead to the conclusion that 
MEFV plays a role in a negative-feedback loop, specific for Th1 and 
proinflammatory-mediator activation of myelomonocytic cells [20]. 
The interaction of pyrin with two proteins, ASC (Apoptosis-associated Speck-like 
Protein with CARD (the caspase-recruitment domain)) and PSTPIP1 (proline serine 
threonine phosphatase interacting protein 1) explains its role in the cellular pathways 
[22,25]. ASC is a 195 amino acid protein, which plays an important role in caspase-1 
activation and IL-1β secretion, NF-κB activation and apoptosis [22]. Pyrin interferes 
with the interaction of cryopyrin with ASC and prevents the cryopyrin-mediated 
inflammation through IL-1β processing [22,24,25].  
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Figure 1.2. Interaction of pyrin with ASC and PSTPIP1 [25] 
PSTPIP1 is an adaptor protein, which is localized in both neutrophils and monocytes 
as well as in lung, spleen, thymus and small intestine. It participates on the regulation 
of actin-based structures. The interaction of PSTPIP1 with pyrin leads to the 
positioning of pyrin on the signaling pathway so that it could sense and/or modulate 
the signals transduced by the cytoskeleton. This interaction of pyrin with actin 
filaments may explain the success of the colchicine treatment in FMF [22]. 
1.4 MEFV mutations/polymorphism, their effects and geographical distribution 
Since MEFV gene has been cloned, more than 70 mutations have been reported 
[4,10]. Four main missense mutations and one polymorphism constitute the majority 
of the mutations/polymorphism encountered in patients of Mediterranean ancestry.   
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Table 1.1. Five main mutations/polymorphism on MEFV gene [26] 
Exon  
Mutation/ 
Polymorphism 
Codon Change Amino Acid  
2 E148Q GAG → CAG Glu → Gln  
M694V ATG → GTG Met → Val  
M694I ATG → ATA Met → Ile 
M680I ATG → ATC Met → Ile 
10 
V726A GTT → GCT Val → Ala 
 
M694V mutation is considered to cause a most severe disease phenotype since it 
causes renal amyloidosis in many of the reported cases, especially from Armenia, 
Israel and Lebanon [4]. In addition to this, patients with M694V homozygous 
mutation have an earlier age of onset and show a higher frequency of arthritis [6]. On 
the other hand, patients with compound heterozygous mutation/polymorphism like 
the V726A-E148Q mutation/polymorphism have severe amyloidosis in most of the 
cases. This might point the need to prescribe colchicine to the patients having 
mutations other than M694V [27]. 
Figure 1.3. Most commonly observed /polymorphism on MEVF gene [28] 
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E148Q is reported to be the most frequent MEFV mutation in the general population. 
It is reported that patients with E148Q mutation have higher MEFV mRNA levels 
compared to patients with M694V mutation [29]. However, this mutation causes 
either a milder form or asymptomatic FMF [22]. Furthermore, this mutation shows a 
higher frequency in general population than observed in patients. There are some 
suggestions that E148Q might be a polymorphism augmenting the inflammation state 
[30]. 
The accumulation of the mutations on the 3’ end of the MEFV mRNA makes it 
predisposed for nuclease attacks. Besides, MEFV mRNA stability might be modified 
by these mutations. Furthermore, the alteration in MEFV mRNA expression level 
due to the number and type of the mutations gives rise to the possibility that MEFV 
might be involved in its own expression regulation [29]. 
The frequency of different mutations of MEFV in different populations varies: the 
M694V mutation is most commonly observed among Jews, Turks and Armenians; 
whereas the M680I is majorly observed among Armenians and the M694I is 
observed among Arabs. The Turkish population has the highest carrier frequency for 
E148Q [9].  
Despite the differences in the frequencies of the mutations, the appearance of the 
same mutations and the haplotypes in a wide range of populations separated 
geographically, points to a common ancestral genetic pool for these populations [9]. 
 
Figure 1.4. The spread of the M694 V and V726A mutations from the Middle 
East [9] 
8 
 
1.5 MEFV Mutations/polymorphism and HLA-B*51 frequencies in BD 
MEFV mutations are also observed in BD patients. Patients with vascular 
involvement from Turkey and France, where both FMF and BD are frequent, have 
shown higher frequencies of MEFV mutations [19]. Nevertheless, BD is a multigenic 
disease [13]. HLA-B*51, a MHC class I antigen, is found in 60-70% of BD patients 
[19,21].  Two suballeles of HLA-B*51, HLA-B*5101 and HLA-B*5108 are mainly 
found in BD patients. These suballeles have the ability to bind specific peptides and 
natural killer (NK) cells [31]. The aetiology of BD is still unknown but the 
augmentation of the neutrophilic reaction is known as the main reason of the disease 
development [32]. An infectious agent may be involved in the pathology of BD to 
trigger the inflammation like in autoinflammatory disorders but an adaptive response 
is also supported via bacterial persistence or autoantigen-activated dendritic, T or B 
cells. Thus, BD may be an autoinflammatory disease with MEFV involvement, as 
well as an autoimmune disease with HLA-B*51 involvement [21]. 
1.6 The Major Histocompatibility Complex 
The human major histocompatibility complex region (MHC) is located in the short 
arm of the 6th chromosome [33] as shown in Figure 1.5 below. It is found in all 
vertebrate species and has a role in the recognition of self from non-self. Thus it also 
has a role in the regulation of the immune function [34]. 
 
Figure 1.5 Genomic location of HLA region [34] 
The MHC is clustered in three gene classes according to their structure and function. 
These genes are inherited in a co-dominant way, meaning that alleles on both 
chromosomes code for a protein product. In order to indicate the different 
combinations of MHC genes, "MHC haplotype" term is frequently used [34]. 
9 
 
Class I region is composed of highly polymorphic genes (HLA-A, B and C) 
encoding molecules which are expressed in the membranes of many cells in different 
tissues. These molecules bind self and foreign peptides to present them to CDS 
cytotoxic T cells. The class II genes (HLA-DR, DQ, and DP) are only expressed in 
antigen presenting cells, for the presentation of endogenous peptides to CD4 helper T 
cells. The molecules of these two classes are produced in endoplasmic reticulum 
(ER) [34]. 
The third class is located between the class I and class II regions. Genes of class III 
region encode many humoral factors (such as complement components, heat shock 
proteins and tumor necrosis factor) having an immunoregulatory function [34]. 
Class I genes are formed by many exons coding for specific regions of the proteins; 
namely, the class I molecules. The first exon encompasses a signaling sequence 
needed for the initiation of the transcription. The second, third and fourth exons 
encode respectively alpha 1, alpha 2, and alpha 3 extracellular domains. Finally, the 
transmembrane and cytoplasmic segments are coded by exons 5, 6, 7. A beta-
immunoglobulin chain, encoded by a gene on the 15th chromosome, is associated 
with the alpha heavy chain of the class I molecules [34,36]. This motif constitutes the 
functional MHC molecule [36]. 
The second and the third domains of the class I molecules conjugate to form a 
peptide binding groove, "Bjorkman's groove", named after the researcher who 
demonstrated it by crystallography. It comprises beta pleated sheets and alpha helices 
as shown in the Figure 1.6 [34].  
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Figure 1.6 The model structure of the class I and class II molecules [34] 
These grooves contain discrete pockets, which are involved in the binding of the 
peptide amino acid side chains: B and F binding pockets. Most of the mutations are 
observed in these peptide binding regions.  Thus each variant bind a unique range of 
peptide ligands [36]. 
The implication mechanisms of the class I molecules in human diseases are not well 
known; however, molecular mimicry (shared amino acid sequence between 
microorganisms and MHC molecules) and preferential binding of certain viral or 
auto-peptides to class I and II molecules may explain the onset of these diseases [34]. 
1.7 Frequencies of FMF and BD 
FMF and BD have also shown epidemiologic similarities [3]. Both diseases are 
frequent in people from Mediterranean descent [13]. The frequency of FMF in 
Turkey is estimated to be 1:1000 and the carrier rate is 1:5 [6]. The estimated 
frequency of FMF in Armenians living in Turkey is approximately 7:1000 and the 
carrier rate differs between 1:5 and 1:16 [37]. On the other hand, the frequency of 
BD in Turkish patients is approximately 4:1000 and the carrier rate is 1:4 [31,38]. 
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For the Armenians living in Turkey, the BD frequency is estimated to be less than 
2:1000 [37] and the carrier rate is still unknown. 
1.9 Aim of the Study 
The aim of this study was to analyze the frequencies of the five most common 
mutations/polymorphisms in MEFV and also HLA-B*51 allele frequencies in 
Armenian and Turkish populations living in the same environment, namely in 
Istanbul. 
The results obtained from this thesis are expected to give an explanation for the 
difference in the frequency of FMF and BD in these two populations. Furthermore, 
the carrier frequency of BD in Armenians living in Turkey can be calculated.  
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2. MATERIALS and METHODS 
2.1. Materials and Laboratory Equipment 
2.1.1. Used Equipments 
Appendix A displays the equipments used in this project. 
2.1.2. Used Chemicals, Enzymes, Markers and Buffers 
Chemicals, enzymes, markers and their related suppliers are given in Appendix B. 
Appendix C displays the preparation and the composition of buffers and solutions. 
2.2. Collection and Storage of Saliva Samples 
Saliva samples are collected from 100 Armenian working in the administration 
department of Armenian schools in Istanbul and from 100 Turkish students studying 
in Cerrahpaşa Medical Faculty. A questionnaire, shown in Appendix D, is given to 
the subjects before the collection of the samples. According to the selection criteria, 
the subjects have to be older than 18 and have to give their consent (shown in 
Appendix E) for the study.  Saliva samples are collected in OrageneTM vials [39]. 
The samples are kept in room temperature. 
2.3. DNA Isolation from Saliva Samples 
The OrageneTM vials contain a DNA preserving liquid in their lids which mixes with 
the saliva once the subject caps the vial. Before the purification step, the sample has 
to be incubated in a water incubator at 50oC for a minimum of 1 hour. This step is 
performed to ensure the release of DNA from the cells and the inactivation of 
nucleases. 
The saliva is than divided into four 1.5 mL microcentrifuge tubes, each containing 
approximately 1 mL of sample. 40 mL (approximately 1/25th of the volume) 
Oragene•DNA Purifier is added in each tube. This step is needed for the precipitation 
of the impurities and inhibitors. Incubation on ice for 10 minutes is performed for 
effective removal of the impurities.  
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The four tubes are centrifugated for 3 minutes in 1500 g at room temperature. The 
supernatants are collected and combined in a 15 mL centrifuge tube. The pellets are 
discarded. 
4 mL (equal volume) 95-100% ethanol at room-temperature is added for the 
precipitation of DNA in the form of fibers. In some cases DNA might not be visible. 
For the fully precipitation of the DNA, samples are kept in room temperature for 10 
minutes. 
Centrifugation for 10 minutes is performed at room temperature at 1100 g. The 
supernatants are discarded and the DNA pellet is rehydrated by 500 µL TE buffer. 
An incubation of the samples overnight at room temperature or 10 minutes in 500C is 
recommended for the effective dissolving.  
2.4 DNA Amount, Purity and Working Solution Calculations 
The absorbance values measured at 260, 280 and 320 nm are used for the calculation 
of the isolated DNA amount and purity. The DNA amount is calculated via the 
equation 2.1, which is the multiplication of the difference between absorbances at 
260 and 320 nm (giving the absorbance of the DNA alone) by the dilution factor and 
the absorbance constant ( it is assumed that 1 OD is equivalent to  50 µL of DNA). 
 
2.1 
DNA purity is calculated via the equation 2.2 : 
 
     
    2.2 
In order to obtain comparable band patterns in genotyping, DNA concentrations are 
adjusted to 50ng/µL in 250 µL by dilutions from stock DNA. These dilutions serve 
also as aliquots preventing the contamination of the stock DNA. 
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2.5. MEFV Genotyping 
2.5.1 Polymerase Chain Reaction (PCR) 
Isolated DNAs from saliva samples are used as templates for the PCR reactions 
performed for the amplification of the sequences of interest containing the related 
MEFV SNPs. A standard mixture is prepared for all five mutations/polymorphism 
with relative primers.  
Table 2.1 Standard PCR mix 
Ingredient Stock 
Concentration 
Volume Final Concentration 
Taq Buffer  10X 2 µL  1X 
MgCl2 25 mM 1.5 µL  1.875 mM 
Forward Primer  10 pmol/µL 1 µL  0.5 µM  
Reverse Primer  10 pmol/µL 1 µL  0.5 µM  
dNTP mix  2 mM 0.4 µL  40 µM 
Taq Polymerase  5 U/µL 0.2 µL  0.05 U/µL 
dH2O  − 7.9 µL  − 
Template DNA  50 ng/µL 2 µL  100 ng 
Q Solution 5X 4 µL  1X 
FINAL  20 µL    
 
2.5.1.1 Oligonucleotide Primers 
The primers used for the PCR reactions were previously chosen and prepared by my 
lab coworkers. They were confirmed to bind the desired sequence of MEFV gene by 
Amplify 3X software [40]. This software is also able to calculate the efficiency of 
binding and the amplicon sizes. 
The hairpin, heterodimer and self dimer analysis of the primer sets were assessed 
with the SciTools on the IDT DNA website [41]. 
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Table 2.2 Oligonucleotide primers 
SNP Primer Sequence Amplicon 
Size 
Reference 
MEFV F-5'-ATATTCCACACAAGAAAACGGC-3' 
E148Q R-5'-GCTTGCCCTGCGCG-3' 
244 bp [42] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
M680I R-5'-AGGGCTGAAGATAGGTTGAA-3' 
360 bp [30] 
MEFV F-5'-GCTACTGGGTGGTGAT*CAT-3' 
M694V R-5'-AGGGCTGAAGATAGGTTGAA-3' 
215 bp [30] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
M694I R-5'-CTGGACGCCTGGTACTCATTTTT*C-
3' 
195 bp [30] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
V726A R-5'-AGGGCTGAAGATAGGTTGAA-3' 
360 bp [30] 
 
2.5.1.2 PCR Cycle Conditions 
A general PCR protocol, shown in Table 2.3, was designated for all the mutations 
with the exception of E148Q polymorphism which has a more complicated protocol 
with two different loops containing two different annealing temperatures (Table 2.4). 
For the four mutations, only the annealing temperatures differ in protocols (shown in 
Tables 2.5 and 2.6). 
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Table 2.3 General PCR cycle conditions 
Repeat 
Number  
  
Degree  Time  Phase  
1 94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
Variable 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 72 °C  10 minutes  Final Extension  
Table 2.4 PCR conditions for E148Q  
Repeat 
Number 
Degree  Time  Phase  
1 96 °C  5 minutes  Initial Denaturation  
96 °C  30 seconds  Denaturation  
64 °C  30 seconds  Annealing  5 
72 °C  30 seconds  Extension  
96 °C  30 seconds  Denaturation  
62 °C  30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 72 °C  10 minutes  Final Extension  
Table 2.5 PCR conditions for M680I, V726A and M694V  
Repeat 
Number  
  
Degree  Time  Phase  
1 94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
55 °C 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 72 °C  10 minutes  Final Extension  
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Table 2.6 PCR conditions for M694I  
Repeat 
Number  
Degree  Time  Phase  
1 94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
59 °C 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 72 °C  10 minutes  Final Extension  
2.5.2 Agarose Gel Electrophoresis of PCR Products 
For the observation of the PCR products of the five MEFV mutations/polymorphism 
analyzed in this thesis, 1% agarose gel is sufficient due to the sizes of the amplicons 
varying between 195 and 360. Since the right percentage of agarose gel is important 
for observing the PCR bands, mini and midi gels are prepared meticulously: Mini 
gels contain 0.5 g agarose dissolved in 50 mL of 1X TBE buffer as well as 0.5 
µg/mL ethidium bromide, midi gels contain 1.5 g agarose dissolved in 150 mL of 1X 
TBE buffer as well as 0.5 µg/mL ethidium bromide. In order to assess the relative 
lengths of the PCR products, 1 kb ruler (Fermentas) is loaded into the first wells of 
the gels. 6 µL of the PCR products are mixed with 1 µL of 6X loading dye 
(Fermentas) to ease the precipitation and the observation of relative position with 
naked eye. The gels are run for an average of 20-25 minutes in 120V into 1X TBE 
buffer. The results are monitored via transilluminator under UV light, and pictures 
are taken via UV PhotoMW software.  
2.5.3 Restriction Enzyme Digestion of PCR Products 
Restriction enzyme digestions’ protocols were given by the supplier of the enzymes. 
Nevertheless EnzymeX software was also used for the virtual performance of the 
enzyme digestion for its confirmation. The general protocol is given in table 2.7 and 
the restriction enzymes and expected fragment sizes are given in table 2.8 below 
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Table 2.7 Restriction Enzyme Digestion mixture  
Ingredient 1X amount 
10X reaction buffer 2 µL  
dH2O 5 µL  
Restriction Enzyme (10 U/µL) 1 µL 
Amplicon 12 µL  
Final Volume 20 µL  
According to the restriction enzyme digestion protocol, the PCR products are left 
overnight with the enzyme mix at 37 °C for efficient digestion. An additional step 
at80 °C for 30 minutes is needed for the inactivation of the enzyme leading to 
digestion arrest. 
Table 2.8 Restriction Enzymes used for each mutation/polymorphism and expected 
fragment sizes.  
SNP  Restriction 
Enzyme  
Amplicon 
(bp)  
Expected Fragments 
E148Q AvaI 244 Wild Type: 3 fragments (92+83+69) 
Mutant: 2 fragments (161+83) 
M680I HinfI 360 Wild Type: 2 fragments (126+234) 
Mutant: 1 fragment (360) 
M694V PagI 215 Wild Type: 2 fragments (200+15) 
Mutant: 1 fragment (215) 
M694I MboII 195 Wild Type: 1 fragment (195) 
Mutant: 2 fragments (182+13) 
V726A AluI 360 Wild Type: 1 fragment (360) 
Mutant: 2 fragments (320+40) 
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2.5.4 Agarose Gel Electrophoresis of Restriction Enzyme Digested PCR 
Products 
Different agarose gel concentrations are needed for the genotyping of different 
mutations/polymorphism, varying between 1% and 4%. The digested fragments of 
E148Q products are run in 4%, M680I and V726A digested fragments were run in 
2%, M694I and M694V digested fragments were run in 3.5% mini or midi agarose 
gels at 120 V for a minimum of 30 minutes in 1X TBE buffer. Low range marker 
(Fermentas) is used for the calculation of relative lengths of the products. 12 µL of 
RE digestion products are mixed with 2 µL of 6X loading dye (Fermentas) with the 
exception of E148Q products, from which 15 µL of PCR products are mixed with 
3µL of 6X loading dye. 
2.5.5 Genotyping 
The analysis of the gel photos of the RE digested PCR products are performed for the 
genotyping. The expected bands were determined via the EnzymeX software, as 
shown in figures 2.1, 2.2, 2.3, 2.4, 2.5. Genotyping was done blindly by myself, my 
lab partners Sinem KARAMAN, and Duygu KUZUOĞLU, and by my advisor Dr 
Eda TAHİR TURANLI. 
 
Figure 2.1 E148Q expected restriction enzyme fragment sizes 
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Figure 2.2 M694V expected restriction enzyme fragment sizes 
 
Figure 2.3 M694I expected restriction enzyme fragment sizes 
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Figure 2.4 M680I expected restriction enzyme fragment sizes 
 
 
Figure 2.5 V726A expected restriction enzyme fragment sizes 
2.6 HLA Genotyping 
Two types of Olerup SSP HLA kits were used for the determination of the presence 
of the HLA-B*51 allele and its subtype: HLA-B low resolution and HLA-B*51 kits 
(Qiagene). The genotyping protocols for HLA are given by the suppliers of the kit. 
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 The Micro SSPTM Seramates HLA Class I DNA Typing kit (One Lambda) was also 
used for one part of the study as well as for confirmation of the Olerup results.  
 The optimum concentration of DNA for HLA genotyping is 30 ng/µL. It is 
implicated in the manual that non-specific amplifications might occur with samples 
exceeding 50 ng/µL. 
2.6.1 Olerup SSP Kit  
2.6.1.1 PCR Amplification 
A 48-well plate, supplied with its primers in specific positions, is used for HLA 
genotyping.  A master mix is prepared for all 48 wells of the PCR plate, as shown in 
Table 2.9, 2.10 and 2.11. 
Table 2.9 Standard PCR mix-1 for HLA-B low resolution 
Ingredient Volume 
PCR Master Mix  
 without Taq 
3 µL x 53 
Taq Polymerase  
 
 
4.2 µL  
  FINAL  163,2 µL 
3 µL of the standard mix-1 is added into well No. 48 - the well with the negative 
control primers. Then 7 µL is added to well 48. 
Table 2.10 Standard PCR mix-2 for HLA-B low resolution 
Ingredient Volume 
Standard Mix-1 160,2 µL 
DNA 
 
 
2 µL  x 52 
dH2O 5 µL x 52 – 4,2 µL 
  FINAL  519,7 µL 
10 µL of the Standard Mix-2 is added in each 47 wells. Than the PCR plate is closed 
with the provided lids. 
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Table 2.11 Standard PCR mix-2 for HLA-B low resolution 
Ingredient Stock 
Concentration 
Volume Final Concentration 
DNA  30 ng/ µL 2 µL x 45 2,4 µg 
PCR Master Mix  
 without Taq 
 3 µL x 45 1.875 mM 
Taq Polymerase  
 
 
5 U/µL 3,6 µL   U/µL 
dH2O  − 5 µL x 45 – 3,6 µL − 
    FINAL  450 µL    
10 µL of the master mix is added to each of the 40 wells. Than the PCR plate is 
closed with the provided lids. 
A standard PCR cycle condition is used for both kits, as given in the Table 2.12. 
Table 2.12 General PCR cycle condition 
Repeat 
Number  
  
Degree  Time  Phase  
1 94 °C  2 minutes  Initial Denaturation  
94 °C 10 seconds  Denaturation  
10 
65 °C  60 seconds  Annealing and extension 
94 °C 10 seconds  Denaturation  
61 °C  30 seconds  Annealing 20 
72 °C  30 seconds  Extension  
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2.6.1.2 Agarose Gel Electrophoresis 
2% agarose gel is prepared in 0.5 X TBE buffer. The gel is stained with 5 µL per 100 
mL gel solution of ethidium bromide (10 mg/mL). The gel is run in 0.5 X TBE for 
15-20 minutes at 8-10 V/ cm. 
2.6.1.3 Documentation and Interpretation 
The gel is documented by photography with a UV transilluminator. The presence and 
absence of specific PCR products is recorded. The specific PCR products help in the 
interpretation of the results. 
The relative lengths of the internal positive control bands are also recorded. These 
control bands help in the correct orientation of the typing. Lanes without control 
band or specific PCR products are repeated. 
The interpretation is done via HELMBERG-SCORE® Virtual Sequencing software 
(Appendix F). 
2.6.2 Micro SSP Seramates Kit 
2.6.2.1 PCR Amplification 
A 11-well plate, supplied with its primers in specific positions, is used for HLA 
genotyping.  The first well is set for negative control by adding 1µL of Taq 
polymerase to the PCR mix provided by the supplier (One lambda). 1 µL of DNA 
sample as well as 9 µL of the PCR mix with Taq polymerase are put in the first well. 
Than 19 µL of DNA sample is added in the PCR mix with Taq polymerase. 10 µL of 
this mix was applied to the next 10 wells. 
The PCR condition is given in the Table 2.13 below. 
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Table 2.13 PCR Condition For One Lambda Seramates SSP Kit 
Repeat 
Number  
Degree  Time  Phase  
96 °C 130 seconds  Denaturation  
1 
63 °C  60 seconds  Annealing and extension 
96 °C 10 seconds Denaturation 
9 
63 °C 60 seconds Annealing 
96 °C 10 seconds  Denaturation  
59 °C  50 seconds  Annealing 20 
72 °C  30 seconds  Extension  
 
2.6.2.2 Agarose Gel Electrophoresis 
2.5 % agarose gel is prepared in 0.5 X TBE buffer. The gel is stained with 5 µL per 
100 mL gel solution of ethidium bromide (10 mg/mL). The gel is run in 0.5 X TBE 
for 15-20 minutes at 8-10 V/ cm. 
2.6.2.3 Documentation and Interpretation 
The gel is documented by photography with a UV transilluminator. The presence and 
absence of specific PCR products is recorded. The specific PCR products help in the 
interpretation of the results. 
The relative lengths of the internal positive control bands are also recorded. These 
control bands help in the correct orientation of the typing. Lanes without control 
band or specific PCR products are repeated. 
The interpretation is done with the aid of the interpretation table given with the kit 
(Appendix G). 
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2.7 Statistical Analysis 
Non-parametric statistical analyses were performed using chi-square tests. This 
allows to assess the significance of mutation frequencies  between both Turkish and 
Armenian groups with their historical controls, and between each other.  
The P value, which is the level of significance, is calculated to control whether the 
results are obtained by chance. Thus, a lower P value will allow us to reject the null 
hypothesis. The P value intervals are: 
P > 0.05 pointing to the absence of significant difference 
P < 0.05 pointing to a significant difference 
P < 0.01 pointing to a highly significant difference 
P < 0.001 pointing to an extremely significant difference 
Calculations for P value, chi-square and Odds ratio were done with the online tool 
from Simple Interactive Statistical Analysis (SISA) [43]. 
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3. RESULTS 
3.1 DNA Isolation Results 
DNA samples had average concentration of 182.755 ng/µL obtained by OrageneTM 
DNA Self-collection Kit (Genotek). The average value of A260/A280 was 1,83 
(N=213). 
3.2 Demographic Data of the Armenian and Turkish Groups 
The demographic data of the Armenian and Turkish groups are given in the tables 
3.1 and 3.2 below. 
Table 3.1 Demographic properties of the Armenian Group 
Armenian Group                  N=113 
  
Gender Percentage / Number 
Female 82.3 % / 93 
Male 17.7 % / 20 
FMF  4.4% / 5 
BD -- 
Mean Age 42 ± 12 (range 22-84) 
Table 3.2 Demographic properties of the Turkish Group 
Turkish Group                  N=100 
  
Gender Percentage / Number 
Female 68 % / 68 
Male 32 % / 32 
FMF -- 
BD 1% / 1 
Mean Age 24 ± 1 (range 22-31) 
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3.3 Genotype Analysis 
3.3.1 MEFV 
The genotyping is done by counting the alleles from the obtained gel photos with the 
expected RE digestion patterns previously determined via EnzymeX software 
Sample PCR and restriction enzyme results for each mutation analysis are given in 
Appendix H.  
The obtained genotypes are shown in the table 3.3 below. 
Table 3.3 Obtained genotypes in the Armenian and Turkish groups 
SNP Genotype 
Armenian Group 
N= 113 
Turkish Group 
N= 98 
MM 100 92 
MV 13 6 
M694V  
VV - - 
MM 106 95 
MI 7 3 
M694I  
II - - 
MM 105 97 
MI 7 1 
M680I   
II 1 - 
VV 105 94 
VA 8 3 
V726A  
AA - 1 
EE 101 88 
EQ 12 7 
E148Q  
QQ - 3 
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3.3.1.1 Statistical Mutation/Polymorphism Analysis 
Some subjects have been excluded from the data: 3 Turkish subjects - the genotyping 
was not applicable, one suggested Armenian subject for not having Armenian 
ethnicity and one Armenian subject for having a sibling in the study. Additionally 
diseased subjects are also excluded from the statistical analyses. 
 The mutational/polymorphism frequencies of Armenian and Turkish groups are 
given in the tables 3.4 and 3.5 below.  
Table 3.4 Frequencies of five common MEFV mutations/polymorphisms in the 
Armenian group 
SNP 
N=108 
Number of 
Mutations/Polymorphisms 
Mutation/Polymorphism 
Frequency 
M694V  13 6 % 
M694I  6 2.7 % 
M680I   6 2.7 % 
V726A  6 2.7 % 
E148Q  12 5.5 % 
TOTAL 43 19.6 % 
Table 3.5 Frequencies of five common MEFV mutations/polymorphisms in the 
Turkish group 
SNP 
N=97 
Number of 
Mutations/Polymorphisms 
Mutation/Polymorphism 
Frequency 
M694V  6 3.1 % 
M694I  3 1.5 % 
M680I   1 0.5 % 
V726A  5 2.6 % 
E148Q  13 6.7 % 
TOTAL 28 14.4 % 
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We first compared the mutation/polymorphism frequencies between our two groups 
which is shown in table 3.6 below. 
Table 3.6 Mutation/polymorphism analysis between two groups 
SNP 
N=97 the Turkish group 
(194 chromosomes)  
N=108 the Armenian group 
(216 chromosomes) 
M694V  6 (3.1 %) 13 (6 %) 
M694I  3 (1.5 %) 6 (2.7 %) 
M680I   1 (0.5 %) 6 (2.7 %) 
V726A  5 (2.6 %) 6 (2.7 %) 
E148Q  13 (6.7 %) 12 (5.5 %) 
TOTAL 28 (14.4 %) 43 (20 %) 
 
The mutational/polymorphism frequencies of healthy Armenian and healthy Turkish 
groups are compared with historic controls, the frequency data given in the tables 3.8 
and 3.9 below. 
Table 3.7 Mutation/polymorphism analysis – comparison with historic controls in 
Turks 
SNP 
N=97 the Turkish group 
(194 chromosomes)  
Turkish Controls [44] 
 (N=100) 
(200 chromosomes) 
M694V  6 (3.1 %)  3 (1.5 %) 
M694I  3 (1.5 %) 0 
M680I   1 (0.5 %)  5 (2.5 %) 
V726A  5 (2.6 %)  2 (1 %) 
E148Q  13 (6.7 %) 12 (6 %) 
TOTAL 28 (14.4 %) 22 (11 %) 
31 
 
Table 3.8 Mutation/polymorphism analysis – comparison with historic controls in 
Armenians 
SNP 
N=108 the Armenian group 
(216 chromosomes) 
Armenian  Controls [45] 
(N=250)  
(500 chromosomes)  
M694V  13 (6 %) 24 (4.7%) 
M694I  6 (2.7 %) -- 
M680I   6 (2.7 %) -- 
V726A  6 (2.7 %) 23 (4.6%) 
E148Q  12 (5.5 %) 17 (3.4%) 
TOTAL 43 (20 %) 64 (12.8 %) 
 
There was no significant difference in the MEFV mutation/polymorphism 
frequencies between the Turkish subjects and Turkish historic controls. In addition to 
this, no significant difference was found in the MEFV mutation/polymorphism 
frequencies between the Armenian subjects and Armenian historic controls. On the 
other hand, when the mutation/polymorphism frequencies of MEFV between Turkish 
and Armenian subjects are compared there was not any significant difference either. 
However, in M680I mutation, a trend for significance was observed (95% CI, 
p=0.0847, χ2=2.971, Table 3.8).   
Table 3.9 Statistical analysis of mutations/polymorphism 
Armenian Group / 
Turkish Group 
Armenian Group / 
Historical Controls 
Turkish Group / 
Historical Controls 
 
χ2  P Val OR χ2  P Val OR χ2  P Val OR 
M694V 1.807 0.18 1.5 0.41 0.52 1.25 1.069 0.30 1.35 
M694I 0.691 0.41 1.42 -- --  3.1 0.08 - 
M680I 3.016 0.08 3.31 -- --  2.51 0.11 2.95 
V726A 0.015 0.90 1.04 1.197 0.27 1.66 1.355 0.24 1.45 
E148Q 0.207 0.65 1.10 1.65 0.20 1.63 0.072 0.79 1.06 
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3.1.2 HLA-B*51  
The genotyping was done with HELMBERG-SCORE® Virtual Sequencing software 
for the Olerup kit and with the table provided by the supplier for the One lambda 
Seramates kit. 
First, we compared the HLA-B*51 frequencies of our two groups, which is shown in 
the table 3.10 below. 
Table 3.10 HLA-B*51 phenotypes of the Armenian and the Turkish Groups 
 Armenian Group 
N=110 
Number of phenotypes (%) 
Turkish Group 
N=93 
Number of phenotypes (%) 
HLA-B*51 30 (% 27.2 ) 19 (% 20.4)  
 
The observed HLA-B*51 phenotypes of the two groups were than compared with 
historical controls. The data are given in the tables 3.11 and 3.12 below. 
Table 3.11 HLA-B*51 phenotype analysis – Comparison with historical controls in 
Armenians 
 Armenian Group 
N=110 
Number of phenotypes/ 
Percentage 
Armenian Controls [46] 
N=100  
Number of phenotypes/ 
Percentage 
HLA-B*51 30 (% 27.2 ) 10.4  (% 10.4) 
 
Table 3.12 HLA-B*51 phenotype analysis – Comparison with historical controls in 
Turks 
 Turkish Group 
N=93 
Number of phenotypes/ 
Percentage 
Turkish Controls [47] 
N=228 
Number of phenotypes/ 
Percentage 
HLA-B*51 19 (% 10.2)  72 (% 15.8) 
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There was no significant difference in the HLA-B*51 frequencies between the 
Turkish and Armenian subjects. No significant difference was found in the HLA-
B*51 frequencies when Turkish subjects were compared with historic controls from 
the literature. On the other hand, when the HLA-B*51 frequencies between 
Armenian subjects and Armenian historic controls are compared there was a 
significant difference which can be seen in the table 3.13 below (χ2=14.153, 
p=0.0001, OR=1.63). 
Table 3.13 Statistical analysis of HLA-B*51 frequencies 
 Armenian Group / 
Turkish Group 
Armenian Group / 
Historical Controls 
Turkish Group / 
Turkish Historical 
Controls 
 χ2  P Val OR χ2  P Val OR χ2  P Val  OR 
HLA-
B*51 
0.875 0.350  1.18 14.153  0.0001  1.63 2.591  0.1074 1.39 
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4. CONCLUSION & DISCUSSION 
The results obtained from this study confirm the literature on the frequencies of the 
five most common MEFV mutations in general Turkish and Armenian populations 
who live in Turkey.  Subjects showed similar frequency distributions of five most 
common mutations of MEFV, and there was no significant difference in the MEFV 
mutation frequencies between the Turkish subjects and Turkish historic controls as 
well as in Armenian subjects and Armenian historic controls. When the mutation 
frequencies of MEFV between Turkish and Armenian subjects are compared, there 
wasn’t any significant difference either. This result might be caused by population 
stratification or lack of a greater sample pool. However, in M680I mutation, a slight 
trend was observed, which may indicate that this mutation is more common among 
the Armenian population (6 in 108). 
Although these two populations live in the same environment, the FMF frequency is 
higher in Armenian Turkish citizens than in Turkish population. On the other hand, 
the mutation frequencies of MEFV are very high in both groups, unlike the FMF 
disease itself.  
Recent studies have shown that MEFV mutations and polymorphisms are not 
specific to FMF; in fact, they are also found in other inflammatory disorders, such as 
Behçet disease [3,48], ulcerative colitis [49], rheumatoid arthritis [50] and 
polyarteritis nodosa [51]. Also, more recent studies point that there are many patients 
who are clinically FMF but are free of MEFV mutations [52,53]. 
Altogether, these facts might indicate the recessive inheritance pattern of FMF as 
well as the other potential genetic locus or loci that could be related with FMF. 
Results from the HLA-B*51 study confirm the literature for the Turkish group, 
however, the Armenian group have shown a higher frequency than the historic 
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control group. When compared, no significant difference between the Armenian and 
the Turkish group was observed. These results may point to the genetic differences 
between the Armenians living in Turkey and the Armenians living in other countries. 
Also, it may point to another locus or loci, which have a role in the aetiology of 
Behcet disease. 
In further studies, the compound heterozygous samples would be clarified via DNA 
sequencing to calculate the true allelic frequencies of MEFV mutations and 
polymorphisms. Also, the HLA-B*51 frequencies observed in both groups, would be 
confirmed by serological analyses. 
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APPENDIX A 
LABORATORY EQUIPMENT 
Balances    Precisa 620C SCS 
     Precisa BJ 610C 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments  E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes    Gilson Pipetman 20 µL 200 µl, 1000 µl 
     Thermo Finnpipette 10 µL,  
pH meter     Mettler Toledo MP220 
Spectrophotometer   PerkinElmer Lambda25 UV/VIS Spectrometer 
Thermo cycler   Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator   Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top 
44 
 
APPENDIX B 
CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol    Riedel-de Haën 
EtBr     Amresco 
MgCl2     Fermentas 
NaOH     Riedel-de Haën 
Primers    IDT DNA 
NaCl     Carlo Erba 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
     Qiagen 
     Roche 
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ENZYMES 
AluI     Roche 
AvaI     Fermantas 
HinfI     Roche 
MboII     Fermantas 
PagI     Fermantas 
Taq DNA Polymerase  Fermentas 
     Qiagen 
     Roche 
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MARKERS 
Gene RulerTM 1 kb DNA Ladder    Fermentas 
 
 
Gene RulerTM DNA Ladder Low Range  Fermentas 
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APPENDIX C 
BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
Add 1.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
Add 4.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Mini Agarose Gel (3%)  
Agarose     1.5 g 
TBE buffer (1X)   50 mL 
Add 1.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
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Midi Agarose Gel (3%)  
Agarose     4.5 g 
TBE buffer (1X)   150 mL 
Add 4.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
Mini Agarose Gel (4%)  
Agarose     2 g 
TBE buffer (1X)   50 mL 
Add 1.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (4%)  
Agarose    6 g 
TBE buffer (1X)   150 mL 
Add 4.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
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APPENDIX D 
Gönüllü Bilgilendirme ve Olur Formu 
Çalışma Başlığı: Ermeni ve Türk toplumunda MEFV gen mutasyon ve HLA B51 
sıklığı 
Çalışmayı yürüten merkez: İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, 
Romatoloji Bilim Dalı 
 
Ailevi Akdeniz Ateşi ve Behçet Hastalığı, Ortadoğu ve Anadolu halklarında, 
dünyanın diğer yörelerine oranla daha sık görülmektedir. Türkiye’de yapılan 
çalışmalarda Ailevi Akdeniz Ateşi sıklığı 1000’de 1-2.5  arasında değişirken, Behçet 
hastalığının sıklığı 1000’de 4 olarak saptanmıştır. Yakın zamanda İstanbul’da T.C. 
Ermeni kökenli vatandaşlarında yaptığımız öncü bir çalışmada, bu toplumda Ailevi 
Akdeniz Ateşinin Türklere oranla daha sık (% 0.7), Behçet hastalığının ise daha 
nadir olduğunu (< 1/ 500) gözledik. Bu bulgular bize, her iki hastalığın etyolojisinde 
de genetik sebeplerin daha ağır bastığını düşündürdü.   
Son yıllarda Ailevi Akdeniz Ateşi hastalığına MEFV genindeki 
mutasyonların yol açtığı ortaya çıkmıştır.Tanımlanan mutasyonların sayısı 50’den 
fazladır ancak 4 tanesi daha sık görülmektedir; ve bu mutasyonlar hasta kişilerde % 
85, sağlıklı kişilerde ise % 10-20 oranında bildirilmektedir.   
Öte yandan Behçet hastalığı ile HLA B51 geni arasında bir ilişki varolduğu 
da bilinmektedir. HLA B51 taşıyıcılığı, Behçet hastalığı olan bireylerde % 50-80, 
sağlıklı kişilerde ise % 20-30 oranında bildirilmektedir. Behçet hastalığının sıklığı 
toplumdaki HLA B51 taşıyıcılığına paralel seyretmektedir. Örneğin, HLA B51 
sıklığının az olduğu toplumlarda Behçet hastalığı da nadirdir.    
Yukarıda belirttiğimiz nedenlerden ötürü, biz bu çalışmada, T.C. Ermeni ve 
Türk vatandaşlarında MEFV gen mutasyonunu ve HLA B51 gen taşıyıcılığını 
araştırmak istedik. Bu araştırma için tükürük örneği vermeniz yeterli olacaktır. 
Verdiğiniz tükürük örneği, içerdiği kan hücrelerinden DNA ve RNA elde edilmek 
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üzere İstanbul Teknik Üniversitesi, Moleküler Biyoloji ve Genetik laboratuarlarında 
saklanacak ve daha önce bahsettiğimiz genler için çalışılacaktır. Bu araştırmaya 
yaklaşık 200 kişinin (100 Ermeni, 100 Türk) katılması beklenmektedir. 
 Sizden alınmış olan tükürük örneği, sizden alındığını gösteririr herhangi bir 
kişisel bilgi içermeyecektir. Yapılacak bilimsel çalışmalar genellikle çok sayıda 
örnekle yürütülecek ve bu çalışmalardan toplu sonuçlar çıkacaktır. Bu nedenle, 
çalışmaların kısa vadedeki sonuçlarından kişisel olarak sizin veya ailenizin diğer 
bireylerinin yararlanması sözkonusu olmayabilir.  
Bağışladığınız bu tükürük örneğiyle, çalışmaların sonuçlarından herhangi bir 
ticari kazanç beklememeyi taahhüt ediyorsunuz. Bu çalışmaya katılmak için herhangi 
bir ücret ödemeniz de gerekmemektedir. Tükürük vermeden önce aç olmanız ya da 
herzaman almakta olduğunuz ilaçları kesmeniz de gerekmemektedir. 
Bu araştırmaya katılmamakta veya imzaladıktan sonra herhangi bir zamanda 
sebep belirtmeksizin ayrılmakta özgürsünüz.  
Bu çalışmada yer aldığınız takdirde elde edilecek tıbbi bilgiler, her zaman 
kesinlikle gizli kalacaktır. Bununla birlikte kayıtlarınız İstanbul Üniversitesi 
Cerrahpaşa Tıp Fakültesi Romatoloji Bilim Dalı ve fakültenin Etik Komitesinin 
incelemesine açık olacaktır. Araştırmada elde edilecek bilgiler yurt içi ve yurt 
dışında bilimsel toplantılarda ve dergilerde açıklanabilir. Ancak herhangi bir rapor 
ya da yayında hiçbir şekilde kimliğinizi belirtecek bilgi bulunmayacak ve veriler 
izlenerek size ulaşılmayacaktır. Yürümekte olan çalışmaların genel sonuçları 
hakkında Dr. Emire Seyahi’den bilgi alabilir ve herhangi bir sorun olduğu 
takdirde bu doktora 0533 818 42 34 telefon numarasından ulaşabilirsiniz.  
 
Yukarıda gönüllüye araştırmadan önce verilmesi gereken bilgileri içeren 
metni okudum (veya bu metin bana okundu). Bunlar hakkında bana yazılı veya sözlü 
açıklamalar yapıldı. Bu koşullarla söz konusu klinik araştırmaya katılmayı kendi 
rızamla, hiçbir baskı ve zorlama olmaksızın katılmayı kabul ediyorum.  
 
Gönüllünün adı-soyadı:                                                                 İmzası                 
Tarih:................................ 
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Açıklamaları yapan /örneği alan araştırmacının: 
Adı-Soyadı                                                                                     İmzası: 
Rıza alma işlemine başından sonuna kadar tanıklık eden kuruluş görevlisinin: 
Adı-Soyadı                                                                                     İmzası: 
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APPENDIX G 
Sample Questionnaire 
Tarih:........................................................................ 
Ad Soyad:.................................................................................................................................... 
Kod:............................................................................................................................................. 
Doğum Tarihi:............................................................................................................................. 
Cinsiyet:....................................................................................................................................... 
Doğum yeri:................................................................................................................................. 
1) Şimdiye kadar size Behçet hastalığı tanısı kondu mu? 
a) Evet                       b) Hayır                      c) Emin Değilim 
2) Şimdiye kadar size Ailevi Akdeniz Ateşi hastalığı tanısı kondu mu? 
a) Evet                       b) Hayır                      c) Emin Değilim 
3) Tekrarlayan ağız yaraları oluyor mu? (Senede 3’ten fazla) 
a) Evet                       b) Hayır                      c) Emin Değilim 
4) Cinsel bölgenizde tekrarlayan yaralar çıkıyor mu? 
a) Evet                       b) Hayır                      c) Emin Değilim 
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5) Tekrarlayan ateşli veya ateşsis karın ağrısı nöbetleri olur mu? (2-3 gün süren, 
genellikle yatak istirahati gerektiren)  
a) Evet                       b) Hayır                      c) Emin Değilim 
6) Tekrarlayan göğüs ağrısı nöbetleri olur mu? (2-3 gün süren, nefes almayı 
zorlaştıran)  
a) Evet                       b) Hayır                      c) Emin Değilim 
7) Eklemlerinizde 2-3 güren süren kırmızı ağrılı şişlikler olur mu?  
 a) Evet                       b) Hayır                      c) Emin Değilim 
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APPENDIX H 
SAMPLE PCR AND RESTRICTION ENZYME RESULTS 
 
Figure H.1 E148Q PCR results 
 
Figure H.2 E148Q Restriction Enzyme Digestion Results 
 
Figure H.3 M680I PCR results 
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Figure H.4 M680I Restriction Enzyme Digestion Results 
 
 
Figure H.5 M694V PCR results 
 
 
Figure H.6 M694V Restriction Enzyme Digestion Results 
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Figure H.7 M694I PCR results 
 
Figure H.8 M694I Restriction Enzyme Digestion Results  
 
Figure H.9 V726A PCR results 
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Figure H.10 V726A Restriction Enzyme Digestion Results 
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